These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37752892)

  • 21. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
    Tam CS; Brown JR; Kahl BS; Ghia P; Giannopoulos K; Jurczak W; Šimkovič M; Shadman M; Österborg A; Laurenti L; Walker P; Opat S; Chan H; Ciepluch H; Greil R; Tani M; Trněný M; Brander DM; Flinn IW; Grosicki S; Verner E; Tedeschi A; Li J; Tian T; Zhou L; Marimpietri C; Paik JC; Cohen A; Huang J; Robak T; Hillmen P
    Lancet Oncol; 2022 Aug; 23(8):1031-1043. PubMed ID: 35810754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
    Tam CS; Trotman J; Opat S; Burger JA; Cull G; Gottlieb D; Harrup R; Johnston PB; Marlton P; Munoz J; Seymour JF; Simpson D; Tedeschi A; Elstrom R; Yu Y; Tang Z; Han L; Huang J; Novotny W; Wang L; Roberts AW
    Blood; 2019 Sep; 134(11):851-859. PubMed ID: 31340982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
    Leukemia; 2019 Apr; 33(4):969-980. PubMed ID: 30315239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
    Shadman M; Tedeschi A; Mohseninejad L; Yang K; Lamanna N; Xu S; Cohen A; Challagulla S; Xue M; Williams R; O'Brien SM; Brown JR; Tam C
    Blood Cancer J; 2024 May; 14(1):77. PubMed ID: 38697986
    [No Abstract]   [Full Text] [Related]  

  • 28. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.
    Hillmen P; Janssens A; Babu KG; Kloczko J; Grosicki S; Manson S; McKeown A; Gupta I; Chang CN; Offner F
    Acta Oncol; 2016; 55(9-10):1115-1120. PubMed ID: 27494089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
    Chen LS; Bose P; Cruz ND; Jiang Y; Wu Q; Thompson PA; Feng S; Kroll MH; Qiao W; Huang X; Jain N; Wierda WG; Keating MJ; Gandhi V
    Blood; 2018 Nov; 132(21):2249-2259. PubMed ID: 30254130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
    Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
    Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.
    Cadot S; Audebert C; Dion C; Ken S; Dupré L; Largeaud L; Laurent C; Ysebaert L; Crauste F; Quillet-Mary A
    PLoS Med; 2024 Jul; 21(7):e1004430. PubMed ID: 39037964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
    Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
    O'Brien S; Furman RR; Coutre S; Flinn IW; Burger JA; Blum K; Sharman J; Wierda W; Jones J; Zhao W; Heerema NA; Johnson AJ; Luan Y; James DF; Chu AD; Byrd JC
    Blood; 2018 Apr; 131(17):1910-1919. PubMed ID: 29437592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
    Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
    Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
    Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
    Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.